Adaptive Biotechnologies (ADPT) Stock May Be Trading At A Premium Following Its 477% Run

Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT).

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group

Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Adaptive Biotechnologies Corp (ADPT) Stock Down 3.1% but Still O

Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

Adaptive Biotechnologies Stock: 5 Straight Green Days, Up 18%

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma